Thyroid gland metastasis of malignant tumors is observed in 1.9% to 9.5% of histologically examined autopsy cases. Thyroid metastasis from colon cancer is extremely rare and the prognosis is poor. Here we report a case of lung metastasis and thyroid gland metastasis following sigmoid colon cancer surgery. In 2000, a 58-year-old woman underwent a sigmoid colectomy for sigmoid colon cancer. In 2005, a metastatic lung tumor was detected by chest CT. The patient underwent a partial thoracoscopic resection of the left lung in April 2005. On a CT scan taken 3 years and 4 months after the lung resection, a tumor mass was observed in the left lung and a low-absorption region with an unclear border was seen in the left lobe of the thyroid gland. Thyroid aspiration cytology showed adenocarcinoma, and a diagnosis of thyroid gland metastasis from sigmoid colon cancer was made. In April 2008 a subtotal thyroidectomy was performed. Following surgery, the patient underwent chemotherapy with mFOLFOX6 and bevacizumab. Nevertheless a number of lung metastases and expressions of lung metastasis were subsequently observed. Histopathological examination revealed a number of metastases of differentiated papillary adenocarcinoma in the thyroid gland from colon cancer.
Skin metastases from visceral cancers are rare and the reported incidence from all visceral cancers is 1.4% to 10%. Skin metastases from colorectal cancers account for only 5% of metastatic skin cancers, among which scalp metastases are very rare. We describe a 53-year-old man with scalp metastasis derived from sigmoid colon cancer that was diagnosed and surgically resected in 2005. Metastatic lung tumors that developed thereafter were surgically resected and then chemotherapy was administered. However, metastatic brain tumors occurred in 2008, and these were treated by c-knife radiosurgery. Around the same time, a raised lesion that appeared on the scalp was diagnosed as skin metastasis and treated with best supportive care. Thereafter, the brain metastases continued to spread, and the patient died in October 2008.Key words: Skin metastasis -Colon cancer -Scalp metastasis -Brain tumor S kin metastases arising from gastrointestinal cancer are rare, and the theoretical incidence of skin metastases in colorectal cancers is less than 5%.1,2 This case report describes scalp metastasis that developed after surgery for sigmoid colon cancer. Case ReportColonoscopy for a detailed examination of melena revealed sigmoid colon cancer in a 53-year-old man in December 2005 (Fig. 1). Preoperative blood tests revealed carcinoembryonic antigen and cancer antigen 19-9 levels of 6.7 ng/ml and 27.1 U/ml, respectively. Sigmoidectomy was performed in January 2006, and the pathologic diagnosis was well-differentiated adenocarcinoma, lymphovascular invasion (+), T3, N0, M0, stage II. Chest computed tomography (CT) and positron emission tomography imaging in September 2006 revealed an isolated lesion, 6 mm in diameter in the right lung. A metastatic lung tumor was diagnosed (Fig. 2), and in December of the same year the patient underwent thoracoscopic partial resection of the target area in the right lung. The pathologic diagnosis was metastasis from colorectal cancer. The patient received systemic chemotherapy after surgery. However, chest CT images detected tumors in the (Fig. 2), but images obtained in November of the same year revealed recurrence of this tumor and destruction of the right fifth rib. The tumor beds were irradiated with 20 Gy of X-rays to relieve pain and systemic chemotherapy was administered. In April 2008, brain metastases in the left and right frontal lobes were treated by c-knife radiosurgery with target doses of 22 Gy each (Fig. 3). A red, sessile, elastic, firm, raised lesion, 19 mm in diameter, with a glossy surface on the skin of the median area of the occipital region (Fig. 4) was confirmed as skin metastasis of the scalp. This was treated symptomatically. Thereafter, the brain metastases continued to spread, and the patient died in October 2008. DiscussionMetastatic skin cancer is defined as skin metastases from visceral cancer, excluding primary skin cancer and hematologic malignancies. Skin metastases derived from visceral cancers are rare and the reported incidence ranges from 1.4% to 10% of all viscer...
Abstract. For individualized bevacizumab-based therapy, non-invasive biomarkers are necessary. this study assessed the predictive value of plasma vascular endothelial growth factor (VegF)-A, soluble VegF receptor (sVegFr)-1 and sVegFr-2 levels as biomarkers for clinical response and survival in advanced colorectal cancer (crc) patients treated with bevacizumab and modified FOLFOX6 (mFOLFOX6). Forty-six unresectable advanced crc patients and 20 healthy controls were included in this study. crc patients were treated with bevacizumab and mFOLFOX6. Pretreatment plasma VegF-A, sVegFr-1 and sVegFr-2 levels were measured using the multiplex immunoassay. Plasma VEGF-A, sVEGFR-1 and sVEGFR-2 levels were significantly higher in crc patients than in the healthy subjects. the plasma sVegFr-1 levels in the responder patients [complete response (CR)/partial response (PR)] and stable disease (SD) patients were significantly lower than those in the progressive disease (PD) patients (CR/PR vs. PD, p=0.025; SD vs. PD, p=0.032), while the plasma VegF-A and sVegFr-2 levels did not show any significant differences between the two groups of patients. Patients with higher sVEGFR-1 levels showed a significantly poorer progression-free survival (PFS) and overall survival (os) than those with lower VegFr-1 levels. In contrast, VEGF-A and sVEGFR-2 did not show any significant relationship between PFS and OS according to the status of each level. In the multivariate cox proportional hazard regression analysis, sVEGFR-1 levels showed a significant relationship between PFS and OS. These results suggest that plasma sVegFr-1 levels have a predictive value for clinical response and survival in advanced crc patients treated with bevacizumab and mFOLFOX6. Larger scale studies are needed to further validate our results.
Objective: The new concept of cancer stem cells has implications in terms of possible application for novel diagnostic and therapeutic procedures. Recently, the CD133 molecule was reported as a marker of cancer stem-like cells in colorectal cancer (CRC). In this study, we examined the prognostic value of free cancer cells in peritoneal washings from CRC patients after curative resection using multiple molecular markers, including cancer stem-like cells. Methods: A total of 170 CRC patients who had undergone curative surgery were studied. Peritoneal washings of the Douglas cavity were collected and used for cytology and molecular diagnosis. Real-time RT-PCR for carcinoembryonic antigen (CEA), cytokeratin 20 (CK20) and CD133 mRNA was performed to detect free cancer cells. Results: Molecular detection of CEA, CK20 and/or CD133 (CEA/CK20/CD133) mRNA of the peritoneal washings showed a significant correlation with lymph node metastasis and the tumor stage. The overall survival (OS) rates and peritoneal recurrence-free survival (PFS) rates in CEA/CK20/CD133 mRNA-positive patients were significantly lower than those of marker gene-negative patients. CD133/CEA/CK20 mRNAs in peritoneal washings were independent prognostic factors for OS and PFS. Conclusion: Molecular detection of free cancer cells using multimarkers, including cancer stem-like cells in peritoneal washings of post-curative surgery CRC patients, are useful in prognosis prediction.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.